NCT06227468 (GENESIS) is a clinical trial in Healthy, sponsored by Athens LifeTech Park.

Who is sponsoring NCT06227468?

NCT06227468 is sponsored by Athens LifeTech Park.

What condition does NCT06227468 study?

NCT06227468 studies Healthy, Respiratory Disease, Chronic Renal Failure, Cardiovascular Diseases, Metabolic Disease, Psychiatric Disorder, Neurologic Disorder, Gastrointestinal Diseases, Haematologic Disease, Rheumatologic Disease.

Is NCT06227468 still recruiting?

NCT06227468 is currently recruiting now. Last updated 26 January 2024.

Last reviewed 2024-01-26 · How we verify

NCT06227468: GENESIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Map the HLA Genomic Region in the Greek Population

Recruiting now Last updated 26 January 2024

What this trial tests

trial in Healthy in 12,000 participants. Currently enrolling.

Timeline

12 December 2023

Primary endpoint
31 May 2025

31 August 2026

Quick facts

Lead sponsor	Athens LifeTech Park
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	12,000
Start date	12 December 2023
Primary completion	31 May 2025
Estimated completion	31 August 2026
Sites	8 locations across Greece

Conditions studied

Healthy — all drugs for Healthy →
Respiratory Disease — all drugs for Respiratory Disease →
Chronic Renal Failure — all drugs for Chronic Renal Failure →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Athens LifeTech Park

Who can join

18 and older, any sex, with Healthy or Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06227468 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Athens LifeTech Park
Last refreshed: 26 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06227468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing